Gerresheimer AG Announces Supervisory Board Change Reflecting Shareholder Structure Shift

The composition of Gerresheimer AG's Supervisory Board has been updated to align with the company's evolving shareholder structure through the appointment of Klaus Rohrig, who succeeds Dr. Dorothea Wenzel on both the main board and the Audit Committee. This strategic move represents a significant governance adjustment for the global pharmaceutical packaging company, ensuring that board representation accurately reflects current ownership patterns. Rohrig, co-founder and Co-Chief Investment Officer of the Active Ownership Group, will serve until the next Annual General Meeting scheduled for June 3, 2026, when he will stand for formal election alongside three other shareholder representatives.

Dr. Axel Herberg, Chairman of the Supervisory Board, expressed gratitude for Dr. Wenzel's contributions, noting her significant impact on committee functions through her expertise and dedicated service. The transition underscores the dynamic nature of corporate governance in publicly traded companies, particularly those like Gerresheimer that operate across multiple international markets. With operations spanning 40 production sites in 16 countries across Europe, America, and Asia, proper board oversight becomes increasingly critical for maintaining operational excellence and strategic direction.

The timing of this appointment coincides with Gerresheimer's continued expansion following its integration with Bormioli Pharma, which contributed to combined revenues of approximately EUR 2.4 billion in 2024. As a leading provider of drug containment solutions and delivery systems for the pharma, biotech, and cosmetic industries, the company's governance decisions carry substantial weight in the healthcare sector. The board's composition directly influences oversight of critical product lines including digital therapy solutions, on-body devices, syringes, auto-injectors, and various drug containment systems that ensure safe medication delivery to patients worldwide.

Rohrig's assumption of Audit Committee responsibilities places him in a pivotal position for financial oversight and risk management at a time when the company employs approximately 13,600 people globally. The Audit Committee role becomes particularly important given Gerresheimer's position in the MDAX on the Frankfurt Stock Exchange and its extensive international footprint. This governance adjustment reflects the ongoing evolution of shareholder representation in German corporate structures, where supervisory boards play a crucial role in balancing stakeholder interests while ensuring corporate accountability and strategic alignment with market developments.